BioNexus Gene Lab Licensing Deal with Ruanyun Edai Technology Inc. Worth $3.5M
BioNexus Gene Lab Corp. entered into an exclusive 10-year licensing agreement with Ruanyun Edai Technology Inc. (RYET) for the CogniAI document-intelligence platform in the Malaysian healthcare sector. The company will issue 410,000 shares to satisfy the $3.5 million license consideration and an additional 150,000 shares in exchange for 500,000 RYET ordinary shares. BioNexus intends to use the platform to target Malaysia's RM1 billion public healthcare digitalization program.
- Value
- $3.5M
- Counterparty
- Ruanyun Edai Technology Inc.
- Term
- 10 years